Corbus Pharmaceuticals (NASDAQ: CRBP)
Key Data Points
Corbus Pharmaceuticals Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Corbus Pharmaceuticals Company Info
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its products include candidate, Lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in April 2009 and is headquartered in Norwood, MA.
News & Analysis
This Biotech Penny Stock Is Better Than Dogecoin
You might want to avoid buying it, though.
Why Corbus Pharmaceuticals Is Getting Slammed Today
A late-stage clinical failure is weighing heavily on the biotech's stock today.
2 Dirt-Cheap Robinhood Stocks That Could Skyrocket
These cheap companies have upcoming binary catalysts for explosive growth.
3 Awful Stocks Robinhood Investors Love -- and 1 of the Best
Pharmaceutical stocks are popular with Robinhood Investors, including three I would stay away from and one that I wouldn't.
Robinhood Investors Love These 3 Biotech Stocks. Should You?
Could the most popular biotech stocks on Robinhood be the biggest winners for other investors?
3 Stocks Robinhood Investors Love
These have the highest analyst ratings among Robinhood's 100 most popular stocks.
3 Biotech Stocks Robinhood Investors Love, and 1 They Should
Two biotechs have big risks, one is a buy, and the other is a big opportunity to consider.
3 Big Pharma Stocks With Surprising Cannabis Connections
These pharmaceutical giants are already preparing for the legalization of medical marijuana.
Financial Health
General
Q4 2024 | YoY Change |
---|
Revenue Growth Rate
Earnings Per Share Growth Rate
Assets
Q4 2024 | YoY Change |
---|
Liabilities
Q4 2024 | YoY Change |
---|
Ratios
Q4 2024 | YoY Change |
---|
Cash Flow
Q4 2024 | YoY Change |
---|
Valuation
Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
---|
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.